Nicox News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.06.23	Monthly Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights (GlobeNewswire)
03.05.23	Number of voting rights as of April 30, 2023 (GlobeNewswire)
28.04.23	Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China (GlobeNewswire)
26.04.23	Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023 (GlobeNewswire)
26.04.23	New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023 (GlobeNewswire)
24.04.23	Number of voting rigts as of April 24, 2023 (GlobeNewswire)
24.04.23	Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023 (GlobeNewswire)
19.04.23	Nicox Provides First Quarter 2023 Financial and Business Highlights (GlobeNewswire)
14.04.23	Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China (GlobeNewswire)
03.04.23	Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights as of March 31, 2023 (GlobeNewswire)
21.03.23	Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress (GlobeNewswire)
20.03.23	Nicox Reports 2022 Financial Results and Updates Key Future Milestones (GlobeNewswire)
03.03.23	Nicox to Present at Upcoming Scientific Conferences (GlobeNewswire)
01.03.23	Number of voting rights as of February 28, 2023 (GlobeNewswire)
01.03.23	Nicox: Ordinary Shareholder Meeting of February 28, 2023 - Approval of all Resolutions (GlobeNewswire)
13.02.23	Nicox’s Ordinary Shareholder Meeting to be held on February 28, 2023 (GlobeNewswire)
22.11.22	Nicox Raises €10 Million in Private Placement (GlobeNewswire)
22.11.22	Nicox Raises €10 Million in Private Placemen (GlobeNewswire)
07.11.22	Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma (GlobeNewswire)
31.10.22	Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470 (GlobeNewswire)
19.10.22	Nicox Provides Third Quarter 2022 Financial and Business Highlights (GlobeNewswire)
19.09.22	Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial (GlobeNewswire)
16.09.22	Nicox Provides First Half 2022 Business Update and Financial Results (GlobeNewswire)
03.08.22	Nicox to Participate in Financial and Scientific Events in Q3 2022 (GlobeNewswire)
29.07.22	Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors (GlobeNewswire)
20.07.22	Nicox Provides Second Quarter 2022 Financial and Business Highlights (GlobeNewswire)
08.07.22	Nicox: 2022 Extraordinary Shareholder Meeting (GlobeNewswire)
07.07.22	Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology (GlobeNewswire)
03.06.22	Nicox: 2022 Extraordinary Shareholder Meeting (GlobeNewswire)
03.06.22	Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022 (GlobeNewswire)
23.05.22	Nicox (COX): Eye health portfolio targets large markets (EQS Group)
16.05.22	Nicox Announces a New Governance Structure (GlobeNewswire)
04.05.22	Nicox: 2022 Ordinary Shareholder Meeting (GlobeNewswire)
02.05.22	Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470 (GlobeNewswire)
28.04.22	Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones (GlobeNewswire)
11.04.22	Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma (GlobeNewswire)
02.03.22	Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease (GlobeNewswire)
01.03.22	Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China (GlobeNewswire)
23.02.22	Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries (GlobeNewswire)
22.02.22	Nicox Granted New Patent for NCX 4251 in Japan (GlobeNewswire)
21.02.22	Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039 (GlobeNewswire)
08.02.22	Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye (GlobeNewswire)
27.01.22	Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022 (GlobeNewswire)
21.01.22	Nicox Provides Fourth Quarter 2021 Business and Financial Highlights (GlobeNewswire)
05.01.22	Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030 (GlobeNewswire)
16.12.21	Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma (GlobeNewswire)
13.12.21	Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development (GlobeNewswire)
09.12.21	Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Private Placement (GlobeNewswire)
30.11.21	Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease (GlobeNewswire)
17.11.21	Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	202.90	0.15 %	K V
Givaudan	4’058.00	-0.07 %	K V
Lonza Grp	540.80	-0.11 %	K V
Swiss Life Hldg	690.60	-0.20 %	K V
CieFinRichemont	137.05	-0.22 %	K V
Logitech Intl	74.30	-0.75 %	K V
Swiss Re	130.75	-0.91 %	K V
Nestle	74.32	-1.20 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	222.90	-1.46 %	K V

Nachrichten zu Nicox SA provient regroupement

Aktien Top/Flop

Meistgelesene Nachrichten